You are here

Home » Content

Treadmill stres test laboratuarında değerlendirilen hastalarda efor sonuçlarının test öncesi ve sonrası alınan hsCRP ve NT-proBNP düzeylerine göre değerlendirilmesi

Evaluation of treadmill stress test results of patients with their pre and post test hsCRP and NT-proBNP levels

Journal Name:

  • Smyrna Tıp Dergisi

Publication Year:

  • 2012

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Objective: Cardiovascular diseases are globally the most important cause of mortality and morbidity. It is clinically very important to have markers to identify, to treat this population and foreseeing the prognosis. It is curently known that hsCRP and NT-proBNP provide very important data for patients with coronary heart disease (CHD). Aim of the study is to evaluate the clinical benefits of hsCRP and NT-proBNP on detecting cardiovasculer events in patients with suspected CHD. Material and Method: Our study was performed on 81 patients who have or don’t have clasical risk factors (hypertension (HT), diabetes mellitus (DM), smoking, etc.), who describes chest pain and who are undergoing stress test. Study was performed in Istanbul Haseki Education and Research Hospital Treadmill stres Test Unit. Blood samples for hsCRP and NT-proBNP are taken before and after test. Results: As result we can say that Treadmill stress test increases significantly both biomarkers independent of all studied cardiovascular risk factors (p<0,001) and interstingly non-smokers had higher NT-proBNP levels wich is controversial to the references (p=0,013). Conclusion: We can conclude that more studies with more patients and enduring observations are needed to be done to determine what causes these results.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Kardiyovasküler hastalıklar günümüzde halen küresel ölçekte mortalite ve morbiditenin en önemli nedeni olup, yüksek riskteki bu popülasyonu belirlemek, tedavi etmek ve güvenilir bir şekilde prognozu öngörebilmek için kullanılabilecek belirteçler klinikte büyük öneme sahiptir. Güncel bilgiler hsCRP ve NT-proBNP nin koroner arter hastalığı (KAH) olan hastalarda eşsiz prognostik bilgi sağladığını göstermektedir. Çalışmanın amacı, hsCRP ve NT-proBNP’nin birlikte kullanılmasının KAH şüphesi olan hastalarda kardiyovasküler olayları tespit etmede klinik fayda sağlayıp sağlamayacağının değerlendirilmesidir. Gereç ve Yöntem: Çalışmamız koroner arter hastalığının geleneksel risk faktörlerini (hipertansiyon (HT), diyabetes mellitus (DM), sigara vs) taşıyan yada taşımayan, göğüs ağrısı tarifleyen ve eforlu EKG testi ile değerlendirilmesi istenen 81 hasta üzerinde yapıldı. Ekim-2008 ayında İstanbul Haseki Eğitim Araştırma Hastanesi Eforlu EKG Ünitesinde gerçekleştirildi. Hastaların test öncesi ve sonrası kan örneklerinde hsCRP ve NT-proBNP düzeyleri bakıldı. Bulgular: Efor testinin, incelediğimiz tüm kardiyovasküler risk faktörlerinden bağımsız olarak hsCRP ve NT-proBNP düzeylerini anlamlı olarak (p<0,001) arttırdığı sonucuna ulaşıldı. Ayrıca beklenenin aksine sigara içmeyenlerde (p:0,013) NT-proBNP düzeylerinin daha fazla arttığı saptandı. Sonuç: Sonuçlar ilgi çekicidir. Elde ettiğimiz bu sonuçları daha net yorumlayabilmek için, denek sayısının arttırılması ve daha uzun süreli takip gibi faktörlere gerek olabilir diye düşünmekteyiz.
FULL TEXT (PDF): 
PDF icon arastirmax-treadmill-stres-test-laboratuarinda-degerlendirilen-hastalarda-efor-sonuclarinin-test-oncesi-sonrasi-alinan-hscrp-nt-probnp-duzeylerine-gore-degerlendirilmesi.pdf
  • 2
15-21
  • Turkish

REFERENCES

References: 

1. Danesh J, Whincup P, Walker M, Lennon L, Thomson
A, Appleby P, et al. Low grade inflammation and
coronary heart disease: prospective study and updated
meta-analysis. BMJ 2000; 321(7255):199-204.
2. Lagrand WK, Visser CA, Hermens WT, Niessen HW,
Verheugt FW, Wolbink GJ, et al. C-reactive protein as
a cardiovascular risk factor: more than an
epiphenomenon? Circulation 1999; 100(1):96-102.
3. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL,
Rebuzzi AG, Pepys MB, et al. The prognostic value of
C-reactive protein and serum amyloid A protein in severe
unstable angina. N Engl J Med 1994; 331(7):417-
424.
4. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR.
Comparison of C-reactive protein and low density
lipoprotein cholesterol levels in the prediction of first
cardiovascular event. N Engl J Med 2002;
347(20):1557-1565.
5. Levin ER, Gardner DG, Samenson WK. Natriuretic
peptides. N Engl J Med. 1998; 339(5):321-328.
6. Boomsma F, van den Meiracker AH. Plasma A- and Btype
natriuretic peptides: physiology, methodology, and
clinical use. Cardiovasc Res 2001; 51(3):442-429.
7. De Lemos JA, Morrow DA, Bentley JH, Omland T,
Sabatine MS, McCabe CH, et al. The prognostic value
of B-type natiruretic peptide in patients with acute
coronary syndromes. N Engl J Med 2001;
345(14):1014-1021.
8. Gardner RS, Ozalp F, Murday AJ, Robb SD,
McDonagh TA. N-terminal pro-brain natriuretic
peptide: a new gold standard in predicting mortality in
patients with advaced heart failure. Eur Heart J 2003;
24(19):1735-1743.
9. White HD, French JK. Use of brain natriuretic peptide
levels for risk assessment in non-ST elevation acute
coronary syndromes. J Am Coll Cardiol 2003;
42(11):1909-1916.
10. Jernberg T, Stridsberg M, Venge P, Lindahl B. Nterminal
pro brain natriuretic peptide on admission for
early risk stratification of patients with chest pain and
no ST-segment elevation. J Am Coll Cardiol. 2002;
40(3):437-445.
11. Bassan R, Potsch A, Maisel A, Tura B, Villacorta H,
Nogueira MV, et al. B-type natriuretic peptide: a novel
early blood marker of acute myocardial infarction in
patients with chest pain and no ST- segment elevation.
Eur Heart J 2005; 26(3):234-240.
12. Ross R. Aterosclerosis: an inflamatory disease. N Engl
J Med. 1999; 340(2):115-126.
13. Tracy RP. Editorial. Inflamation in cardiovascular
disease. Circulation 1998; 97(20):2000-2002.
14. Ridker PM. Inflamation in atherothrombosis: how to
use high sensitivity c-reactive protein (hs CRP) in
clinical practice. Am Heart Hosp J 2004; 2(4 Suppl
1):4-9.
15. Braunwald E, Fauci AS, Kasper DL, et al. Diabetes
mellitus Harrison. Principles of internal medicine 15
th.Edition. Çev.ed: Saglıker Y. Nobel tıp kitabevleri
2004; 2:2109-2138.
16. Chambers JC, Eda S, Basset P, Karim Y, Thompson
SG, Gallimore JR, et al. C-reactive protein, insulin
resistance, central obesity, and coronary heart disease
risk in Indian Asians from the United Kingdom
compared with European whites. Circulation 2001;
104(2):145-150.
17. Festa A, D’Agostino R Jr, Howard G, Mykkänen L,
Tracy RP, Haffner SM. Chronic subclinical inflamation
as part of the insulin resistance syndrome: The Insulin
Resitance Atherosclerosis Study (IRAS). Circulation
2000; 102(1):42-47.
18. McLaughlin T, Abbasi F, Lamendola C, Liang L,
Reaven G, Schaaf P, et al. Diferentiation between
obesity and insulin resistance in the association with Creactive
protein. Circulation 2002; 106(23):2908-2912.
19. De Beer FC, Hind CR, Fox KM, Allan RM, Maseri A,
Pepys MB. Measurement of serum C-reactive protein
concentration in myocardial ischemia and infarction. Br
Heart J 1982; 47(3):239-243.
20. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi
M, Mitamura H, et al. C-reactive protein as a predictor
of infarct expansion and cardiac rupture after a first Q
wave acute myocardial infarction. Circulation 1997;
96(3):778-784.
21. Berk BC, Weintraub WS, Alexander RW. Elevation of
C-reactive protein in ‘active’ coronary artery disease.
Am J Cardiol 1990; 65(3):168-172.
22. Toss H, Lindahl B, Siegbahn A, Wallentin L.
Prognostic influence of increased fibrinogen and Creactive
protein levels in unstable coronary artery
disease. FRISC Study Group. Fragmin during
Instability in Coronary Artery Disease. Circulation
1997; 96(12):4204-4210.
23. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation
of C-reactive protein and coronary heart disease in the
MRFIT nested case-control study: Multipl Risk Factor
Intervention Trial. Am J Epidemiol 1996; 144(6):537-
547.
24. Mendall MA, Patel P, Ballam L, Strachan D, Northfield
TC. C-reactive protein and its relation to cardiovascular
risk factors: a population based cross sectional study.
BMJ 1996; 27;312(7038):1061-1065.
25. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans
RW, Cushman M, et al. Relationship of C-reactive protein
to risk of cardiovascular disease in the elderly.
Results from the Cardiovascular Health Study and the
Rural Health Promotion Project. Arterioscler Thromb
Vasc Biol. 1997; 17(6):1121-1127.
26. Ross R. The pathogenesis of atherosclerosis: a
perspective for the 1990s. Nature 1993; 362(6423):801-
809.
27. Heinrich J, Schulte H, Schönfeld R, Köhler E, Assmann
G. Association of variables of coagulation, fibrinolysis
and acute- phase with atherosclerosis in coronary and
peripheral arteries and those arteries supplying the
brain. Thromb Haemost 1995; 73(3):374-379.
28. Ridker PM, Cushman M, Stampfer MJ, Tracy RP,
Hennekens CH. Plasma concentration of C-reactive
protein and risk of developing peripheral vascular
disease. Circulation 1998; 97(5):425-428.
29. Haverkate F, Thompson SG, Pyke SD, Gallimore JR,
Pepys MB. Production of C-reactive protein and risk of
coronary events in stable and unstable angina.
European Concerted Action on Thrombosis and
Disabilities Angina Pectoris Study Group. Lancet 1997;
349(9050):462-466.
30. Türkoğlu EI, Gürgün C, Zoghi M, Türkoğlu C. The
relationship between serum C-reactive protein levels
and coronary artery disease in patients with stable
angina pectoris and positive exercise stress test.
Anadolu Kardiyol Derg 2004; 4(3):199-202.
31. Jernberg T, Lindahl B, Siegbahn A, et al. N-terminal
Pro-brain natriuretic peptides during acute myocardial
ischemia induced by dynamic exercise in patients with
angina pectoris. Clin Sci (Colch) 1995; 88:551-556.
32. Marumoto K, Hamada M, Ohyanagi M, Iwasaki T.
Transient increase in plasma brain (B type) natriuretic
peptide after percutaneous transluminal coronary
angioplasty. Clin Sci (Lond). 1995; 88(5):551-556.
33. Huang PH, Lu TM, Wu TC, Lin FY, Chen YH, Chen
JW, et al. Usefulness of combined high-sensitive Creactive
protein and N-terminal probrain natriuretic
peptide for predicting cardiovascular events in patients
with suspected coronary artery disease. Coron Artery
Dis 2008; 19(3):187-193.
34. Ndrepepa G, Kastrati A, Braun S, Mehilli J, Niemöller
K, von Beckerath N et al. N-terminal probrain
natriuretic peptide and C-reactive protein in stable
coronary heart disease. Am J Med 2006; 119(4):355.
35. Stein BC, Levin RI. Natriuretic peptides: physiology,
therapeutic potential, and risk stratification in ischemic
heart disease. Am Heart J 1998; 135(5 Pt 1):914-923.
36. Cheung BM, Kumana CR. Natriuretic peptidesrelevance
in cardiovascular disease. JAMA 1998;
280(23):1983-1984.
37. De Lemos JA, Morrow DA, Bentley JH, Omland T,
Sabatine MS, McCabe CH et al. The prognostic value
of B-type natriuretic peptide in patients with acute
coronary syndromes. N Engl J Med 2001;
345(14):1014-1021.
38. James SK, Lindahl B, Siegbahn A, Stridsberg M,
Venge P, Armstrong P, et al. N-Terminal probrain
natriuretic peptide and other risk markers for the
separate prediction of mortality and subsequent
myocardial infaction in patients with unstable coronary
artery disease: a Global Utilization of Strategies To
Open occluded arteries (GUSTO)-IV substudy.
Circulation 2003; 108(3):275-281.
39. Omland T, Persson A, Ng L, O'Brien R, Karlsson T,
Herlitz J, et al. N-Terminal pro-B-type natriuretic
peptide and long term mortality in acute coronay
syndromes. Circulation 2002 ; 106(23):2913-2918.
40. Libby P. Molecular bases of the acute coronary
syndromes. Circulation 1995; 91(11):2844-2850.
İletişim:
Uz.Dr. Mehmet Burak Aktuğlu
Haseki Eğitim ve Araştırma Hastanesi Dahiliye Kliniği
Fecri Ebcioğlu sokak.Dilek Apt. No: 6/7
1.Levent-İstanbul.
Tel: +90.505.7734483
e-posta: lifeiner@yahoo.com

Thank you for copying data from http://www.arastirmax.com